Volume 21 Issue 7
Jul.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(7): 1138-1142
ZHANG Tingting, GE Huijuan, ZHUANG Xiaosai, REN Lei, NING Bin. Clinical efficacy of sacubitril/valsartan in the treatment of hypertension with left ventricular hypertrophy research[J]. Chinese Journal of General Practice, 2023, 21(7): 1138-1142. doi: 10.16766/j.cnki.issn.1674-4152.003068
Citation: ZHANG Tingting, GE Huijuan, ZHUANG Xiaosai, REN Lei, NING Bin. Clinical efficacy of sacubitril/valsartan in the treatment of hypertension with left ventricular hypertrophy research[J]. Chinese Journal of General Practice, 2023, 21(7): 1138-1142. doi: 10.16766/j.cnki.issn.1674-4152.003068
shu

Clinical efficacy of sacubitril/valsartan in the treatment of hypertension with left ventricular hypertrophy research

doi: 10.16766/j.cnki.issn.1674-4152.003068

  • Department of Cardiology, Fuyang People ' s Hospital, Fuyang, Anhui 236000, China

Funds:

 AHWJ2021b070

 2020byzd354

  • Received Date: 2022-11-28
    Available Online: 2023-08-28
    Abstract
  •   Objective  To explore the role of sacubitril/valsartan in reversing hypertension with left ventricular hypertrophy.  Methods  Ninety patients with hypertension and left ventricular hypertrophy who visited the Department of Cardiology of Fuyang People's Hospital from February to August 2021 were selected as the research objects, including 56 males and 34 females. They were divided into sacubitril/valsartan (A) group, benazepril (B) group and valsartan (C) group according to random numerical table, with 30 cases in each group, and followed up for 12 months. The degree of left ventricular hypertrophy index interventricular septal thickness (IVST), left ventricular posterior wall thickness in diastole (LVPWd), left ventricular mass index (LVMI), left ventricular remodeling and functional indexes such as left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF), the blood pressure compliance rate, clinical efficacy, occurrence of adverse reactions and complications were compared between the three groups.  Results  After treatment, the left ventricular hypertrophy index (IVST, LVPWd and LVMI) and the left ventricular remodeling and functional index (LVEDD and LVEF) of the three groups were significantly improved than those before treatment, all the difference was statistically significant (all P<0.05), and the IVST, LVPWd, LVMI, LVEDD, LVEF of the A group were 10.00 (10.00, 11.00) mm, 10.00 (9.25, 10.75) mm, 81.38 (71.03, 99.34) g/m2, 43.00 (41.00, 47.75) mm and 64.00%(60.00%, 67.00%), which were better than the other two groups, the difference in amplitude of change was statistically significant (P<0.05). The blood pressure compliance rate were 86.67% of the group A, 56.67% of the group B, and 53.33% of the group C. The blood pressure compliance rate in Group A significantly increased, with a statistically significant difference (all P<0.05). There was no significant difference in the incidence of adverse reactions and complications during treatment among the three groups (P>0.05).  Conclusion  Sacubitril/valsartan can relieve the degree of left ventricular hypertrophy in the treatment of hypertension complicated with left ventricular hypertrophy, improve ventricular remodeling and patient prognosis, the effect of reducing pressure is obvious, and the safety is good.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    YILDIZ M, OKTAY A A, STEWART M H, et al. Left ventricular hypertrophy and hypertension[J]. Prog Cardiovasc Dis, 2020, 63(1): 10-21. doi: 10.1016/j.pcad.2019.11.009
    [2]
    诸国华, 孙希鹏, 唐桦, 等. 初发轻度高血压患者内皮功能与左心室肥厚的相关性研究[J]. 首都医科大学学报, 2019, 40(3): 369-373. doi: 10.3969/j.issn.1006-7795.2019.03.009

    ZHU G H, SUN X P, TANG H, et al. Correlation between endothelial function and left ventricular hypertrophy in patients with untreated mild hypertension[J]. Journal of Capital Medical University, 2019, 40(3): 369-373. doi: 10.3969/j.issn.1006-7795.2019.03.009
    [3]
    王杏芬, 高永红, 孙萌. 高血压病患者APN、MMP-9、Ang Ⅱ、ET-1水平与左心室肥厚的相关性研究[J]. 河北医药, 2021, 43(7): 1037-1039, 1043. doi: 10.3969/j.issn.1002-7386.2021.07.017

    WANG X F, GAO Y H, SUN M. Correlation between adiponectin, MMP-9, AngⅡ, ET-1 and left ventricular hypertrophy in patients with hypertension[J]. Hebei Medical Journal, 2021, 43(7): 1037-1039, 1043. doi: 10.3969/j.issn.1002-7386.2021.07.017
    [4]
    冯颖青. 高血压合并左心室肥厚: what's news?[J]. 中华高血压杂志, 2017, 25(7): 616-618.

    FENG Y Q. Hypertension with left ventricular hypertrophy: what's the news?[J]. Chinese Journal of Hypertension, 2017, 25(7): 616-618.
    [5]
    中国高血压防治指南修订委员会. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201904005.htm

    Revision committee of guidelines for the prevention and treatment of hypertension in China. Guidelines for the prevention and treatment of hypertension in China (2018 revision)[J]. Prevention and Treatment of Cardio-Cerebral-Vascular Disease, 2019, 24(1): 24-56. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201904005.htm
    [6]
    中华医学会心血管病学分会高血压学组. 强化血压控制中国专家建议[J]. 中华高血压杂志, 2022, 30(2): 113-117. https://www.cnki.com.cn/Article/CJFDTOTAL-JSWB202208041.htm

    Hypertension group of chinese society of cardiology. Chinese expert advice on strengthening blood pressure control[J]. Chinese Journal of Hypertension, 2022, 30(2): 113-117. https://www.cnki.com.cn/Article/CJFDTOTAL-JSWB202208041.htm
    [7]
    孙宁玲, Jaw-Wen Chen, 王继光, 等. 亚洲高血压合并左心室肥厚诊治专家共识[J]. 中华高血压杂志, 2016, 24(7): 619-627. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201607008.htm

    SUN N L, JAW-WEN CHEN, WANG J G, et al. Asian expert consensus on the diagnosis and treatment of hypertension with left ventricular hypertrophy[J]. Chinese Journal of Hypertension, 2016, 24(7): 619-627. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201607008.htm
    [8]
    束长城, 魏万林. 高血压左心室肥厚的形成机制研究进展[J]. 中国循证心血管医学杂志, 2018, 10(6): 760-762. doi: 10.3969/j.issn.1674-4055.2018.06.35

    SU C C, WEI W L. Research progress in formation mechanism of hypertensive left ventricular hypertrophy[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2018, 10(6): 760-762. doi: 10.3969/j.issn.1674-4055.2018.06.35
    [9]
    韩萌, 习玲, 陈李娟. 老年人原发性高血压左心室肥厚致病机制的研究进展[J]. 中西医结合心脑血管病杂志, 2021, 19(18): 3127-3132. doi: 10.12102/j.issn.1672-1349.2021.18.012

    HAN M, XI L, CHEN L J. Research progress on the pathogenesis of left ventricular hypertrophy in elderly patients with essential hypertension[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2021, 19(18): 3127-3132. doi: 10.12102/j.issn.1672-1349.2021.18.012
    [10]
    朱林, 洪梅. 沙库巴曲/缬沙坦在心血管疾病治疗中的研究进展[J]. 中华老年多器官疾病杂志, 2020, 19(5): 384-387. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLQG202005019.htm

    ZHU L, HONG M. Research progress on sacubitril-valsartan in treatment of cardiovascular diseases[J]. Chinese Journal of Multiple Organ Diseases in the Elderly, 2020, 19(5): 384-387. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLQG202005019.htm
    [11]
    VARDENY O, CLAGGETT B, KACHADOURIAN J, et al. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF Trial (prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure)[J]. Circ Heart Fail, 2018, 11(4): e004745. DOI: 10.1161/CIRCHEARTFAILURE.117.004745.
    [12]
    中国医疗保健国际交流促进会高血压分会, 中国医师协会心血管分会, 中国高血压联盟, 等. 沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议[J]. 中华高血压杂志, 2021, 29(2): 108-114. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202102006.htm

    Hypertension Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare, Cardiovascular Branch of Chinese Medical Doctor Association, Chinese Hypertension Alliance, et al. Chinese expert recommendations on the clinical application of sacubitril/valsartan in patients with hypertension[J]. Chinese Journal of Hypertension, 2021, 29(2): 108-114. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202102006.htm
    [13]
    WANG T D, TAN R S, LEE H Y, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension[J]. Hypertension, 2017, 69(1): 32-41.
    [14]
    CHEUNG D G, AIZENBERG D, GORBUNOV V, et al. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: a randomized, double-blind, 8-week study[J]. J Clinical Hypertension (Greenwich), 2018, 20(1): 150-158.
    [15]
    CHUA S K, LAI W T, CHEN L C, et al. The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and meta-analysis of randomized controlled trials[J]. J Clin Med, 2021, 10(13): 2824. DOI: 10.3390/jcm10132824.
    [16]
    SUPASYNDH O, WANG J, HAFEEZ K, et al. Efficacy and safety of sacubitril/valsartan(LCZ696) compared with olmesartan in elderly asian patients (≥ 65 years) with systolic hypertension[J]. Am J Hypertens, 2017, 30(12): 1163-1169.
    [17]
    DESAI A S, SOLOMON S D, SHAH A M, et al. Effect of sacubitril-valsartan vs. enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial[J]. JAMA, 2019, 322(11): 1077-1084.
    [18]
    MC CAUSLAND F R, LEFKOWITZ M P, CLAGGETT B, et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction[J]. Circulation, 2020, 142(13): 1236-1245.
    [19]
    李晓明, 商睿, 郝盼盼. 苯磺酸氨氯地平与缬沙坦逆转左心室肥厚疗效的对比研究[J]. 中华全科医学, 2016, 14(8): 1330-1331, 1424. doi: 10.16766/j.cnki.issn.1674-4152.2016.08.028

    LI X M, SHANG R, HAO P P. Comparison of benzene sulfonic acid amlodipine and Valsartan in reversion of left ventricularhypertrophy in patients with essential hypertension[J]. Chinese Journal of General Practice, 2016, 14(8): 1330-1331, 1424. doi: 10.16766/j.cnki.issn.1674-4152.2016.08.028
    [20]
    崔启, 袁晓鹏, 张静. 沙库巴曲缬沙坦在高血压患者治疗中应用研究进展[J]. 中华实用诊断与治疗杂志, 2022, 36(8): 859-861. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD202208025.htm

    CUI Q, YUAN X P, ZHANG J. Application of sacubitril/valsartan in the treatment of hypertension[J]. Journal of Chinese Practical Diagnosis and Therapy, 2022, 36(8): 859-861. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD202208025.htm
    [21]
    黎冉, 谢丽娟, 焦长青, 等. 沙库巴曲缬沙坦对不同射血分数心力衰竭患者的疗效及预后[J]. 中华全科医学, 2021, 19(1): 10-13. doi: 10.16766/j.cnki.issn.1674-4152.001716

    LI R, XIE L J, JIAO C q, et al. Clinical effect and prognosis of sacubitril-valsartan in treating heart failure patients with different ejection fraction[J]. Chinese Journal of General Practice, 2021, 19(1): 10-13. doi: 10.16766/j.cnki.issn.1674-4152.001716
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (238) PDF downloads(11) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return